The DOI matches its Crossref record; the references it cites are not checked yet.
Causal relationship between fertility nutrients supplementation and PCOS risk: a Mendelian randomization study
Open accessAbstract
Background: Polycystic ovary syndrome (PCOS), a prevalent endocrine disorder in women of reproductive age, is mainly ameliorated through drugs or lifestyle changes, with limited treatment options. To date, numerous researchers have found that fertility nutrient supplements may benefit female reproductive health, but their direct impact on polycystic ovary syndrome risk remains unclear. Methods: Our research employs Mendelian Randomization to assess how fertility nutrients affect PCOS risk. Initially, we reviewed 49 nutrients and focused on 10: omega-3 fatty acids, calcium, dehydroepiandrosterone, vitamin D, betaine, D-Inositol, berberine, curcumin, epigallocatechin gallate, and metformin. Using methodologies of Inverse Variance Weighting and Mendelian Randomization-Egger regression, we examined their potential causal relationships with PCOS risk. Results: Our findings indicate omega-3 fatty acids reduced PCOS risk (OR=0.73, 95% CI: 0.57-0.94, P =0.016), whereas betaine increased it (OR=2.60, 95% CI: 1.09-6.17, P =0.031). No definitive causal relations were observed for calcium, dehydroepiandrosterone, vitamin D, D-Inositol, and metformin ( P >0.05). Drug target Mendelian Randomization analysis suggested that increased expression of the berberine target gene BIRC5 in various tissues may raise PCOS risk (OR: 3.00-4.88; P : 0.014-0.018), while elevated expressions of curcumin target gene CBR1 in Stomach and epigallocatechin gallate target gene AHR in Adrenal Gland were associated with reduced PCOS risk (OR=0.48, P=0.048; OR=0.02, P =0.018, respectively). Conclusions: Our research reveals that specific fertility nutrients supplementation, such as omega-3 fatty acids, berberine, and curcumin, may reduce the risk of PCOS by improving metabolic and reproductive abnormalities associated with it.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“By the same token, omega-3 fatty acids, which are exceptional at reducing inflammation, have been proven to be beneficial with reference to metabolic parameters and related effects on PCOS risk [68].”
From Nutritional and herbal interventions for polycystic ovary syndrome (PCOS): a comprehensive review of dietary approaches, macronutrient impact, and herbal medicine in management (2025) · cites this paper as [68]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
The citation lists haven’t been fetched yet
References 52 · Cited by 8
Research works printed but not linked: 44
- Wood, 2007, Molecular abnormalities in oocytes from women with polycystic ovary syndrome revealed by microarray analysis, J Clin Endocrinol Metab, 92, 10.1210/jc.2006-2123 · DOI
- Livadas, 2013, Polycystic ovary syndrome: definitions, phenotypes and diagnostic approach, Front Horm Res, 40, 1, 10.1159/000341673 · DOI
- Pasquali, 2013, Glucose intolerance states in women with the polycystic ovary syndrome, J Endocrinol Invest, 36, 10.1007/BF03346757 · DOI
- Bjercke, 2002, Impact of insulin resistance on pregnancy complications and outcome in women with polycystic ovary syndrome, Gynecol Obstet Invest, 54, 10.1159/000067719 · DOI
- Joham, 2014, Contraception use and pregnancy outcomes in women with polycystic ovary syndrome: data from the Australian Longitudinal Study on Women’s Health, Hum Reprod, 29, 10.1093/humrep/deu020 · DOI
- Mirza, 2022, Polycystic ovarian syndrome (PCOS): does the challenge end at conception, Int J Environ Res Public Health, 19, 10.3390/ijerph192214914 · DOI
- Franks, 2006, Development of polycystic ovary syndrome: involvement of genetic and environmental factors, Int J Androl, 29, 10.1111/j.1365-2605.2005.00623.x · DOI
- Sanchez-Garrido, 2020, Metabolic dysfunction in polycystic ovary syndrome: Pathogenic role of androgen excess and potential therapeutic strategies, Mol Metab, 35, 100937, 10.1016/j.molmet.2020.01.001 · DOI · Paper page
- Sirmans, 2013, Epidemiology, diagnosis, and management of polycystic ovary syndrome, Clin Epidemiol, 6, 1, 10.2147/CLEP.S37559 · DOI
- Ozegowska, 2015, The role of insulin and selected adipocytokines in patients with polycystic ovary syndrome (PCOS) - a literature review, Ginekol Pol, 86, 10.17772/gp/2077 · DOI
- Pasquali, 1989, Clinical and hormonal characteristics of obese amenorrheic hyperandrogenic women before and after weight loss, J Clin Endocrinol Metab, 68, 10.1210/jcem-68-1-173 · DOI
- Kiddy, 1992, Improvement in endocrine and ovarian function during dietary treatment of obese women with polycystic ovary syndrome, Clin Endocrinol (Oxf), 36, 10.1111/j.1365-2265.1992.tb02909.x · DOI · Paper page
- Kiani, 2022, Dietary supplements for polycystic ovary syndrome, J Prev Med Hyg, 63, 10.15167/2421-4248/jpmh2022.63.2S3.2762 · DOI
- Ramakrishnan, 2012, Effect of women’s nutrition before and during early pregnancy on maternal and infant outcomes: a systematic review, Paediatr Perinat Epidemiol, 285, 10.1111/j.1365-3016.2012.01281.x · DOI
- Skoracka, 2021, Female fertility and the nutritional approach: the most essential aspects, Adv Nutr, 12, 10.1093/advances/nmab068 · DOI
- Tarín, 2002, Oral antioxidants counteract the negative effects of female aging on oocyte quantity and quality in the mouse, Mol Reprod Dev, 61, 10.1002/mrd.10041 · DOI
- Ebisch, 2007, The importance of folate, zinc and antioxidants in the pathogenesis and prevention of subfertility, Hum Reprod Update, 13, 10.1093/humupd/dml054 · DOI
- Luddi, 2016, Antioxidants reduce oxidative stress in follicular fluid of aged women undergoing IVF, Reprod Biol Endocrinol, 14, 57, 10.1186/s12958-016-0184-7 · DOI
- Zhou, 2016, Chinese herbal medicine for subfertile women with polycystic ovarian syndrome, Cochrane Database Syst Rev, 10, 10.1002/14651858.CD007535.pub3 · DOI
- Yang, 2021, Melatonin: multi-target mechanism against diminished ovarian reserve based on network pharmacology, Front Endocrinol (Lausanne), 12, 10.3389/fendo.2021.630504 · DOI
- Tinggi, 2008, Selenium: its role as antioxidant in human health, Environ Health Prev Med, 13, 10.1007/s12199-007-0019-4 · DOI · Paper page
- Alesi, 2022, Nutritional supplements and complementary therapies in polycystic ovary syndrome, Adv Nutr, 13, 10.1093/advances/nmab141 · DOI
- Gao, 2021, The effect of vitamin D supplementation on blood lipids in patients with polycystic ovary syndrome: A meta-analysis of randomized controlled trials, Int J Endocrinol, 2021, 10.1155/2021/8849688 · DOI
- Li, 2022, Increased homocysteine regulated by androgen activates autophagy by suppressing the mammalian target of rapamycin pathway in the granulosa cells of polycystic ovary syndrome mice, Bioengineered, 13, 10.1080/21655979.2022.2066608 · DOI
- Smith, 2003, Mendelian randomization”: can genetic epidemiology contribute to understanding environmental determinants of disease, Int J Epidemiol, 32, 1, 10.1093/ije/dyg070 · DOI · Paper page
- Chen, 2023, Genomic atlas of the plasma metabolome prioritizes metabolites implicated in human diseases, Nat Genet, 55, 44, 10.1038/s41588-022-01270-1 · DOI
- Hemani, 2018, The MR-Base platform supports systematic causal inference across the human phenome, Elife, 7, 10.7554/eLife.34408 · DOI · Paper page
- Goodarzi, 2011, Polycystic ovary syndrome: etiology, pathogenesis and diagnosis, Nat Rev Endocrinol, 7, 10.1038/nrendo.2010.217 · DOI · Paper page
- Notaro, 2022, The use of metformin in women with polycystic ovary syndrome: an updated review, J Assist Reprod Genet, 39, 10.1007/s10815-022-02429-9 · DOI · Paper page
- Salek, 2019, N-3 fatty acids as preventive and therapeutic agents in attenuating PCOS complications, EXCLI J, 18, 10.17179/excli2019-1534 · DOI
- Zhang, 2018, Elevated CD14++CD16+ Monocytes in hyperhomocysteinemia-associated insulin resistance in polycystic ovary syndrome, Reprod Sci, 25, 10.1177/1933719118756772 · DOI
- Urjumelashvili, 2022, Homocysteine level in patients with polycystic ovary syndrome with and without insulin resistance, Georgian Med News, 331
- Truitt, 2021, Health functionalities of betaine in patients with homocystinuria, Front Nutr, 8, 10.3389/fnut.2021.690359 · DOI
- Yin, 2008, Efficacy of berberine in patients with type 2 diabetes mellitus, Metabolism, 57, 10.1016/j.metabol.2008.01.013 · DOI · Paper page
- Altieri, 2003, Survivin, versatile modulation of cell division and apoptosis in cancer, Oncogene, 22, 10.1038/sj.onc.1207113 · DOI
- Zhen, 2005, Survivin expression and its relation with proliferation, apoptosis, and angiogenesis in brain gliomas, Cancer, 104, 10.1002/cncr.21490 · DOI
- Pan, 2020, Inhibition of survivin induces spindle disorganization, chromosome misalignment, and DNA damage during mouse embryo development, Cell Cycle, 19, 10.1080/15384101.2020.1794545 · DOI
- Li, 2023, A systematic study on the treatment of hepatitis B-related hepatocellular carcinoma with drugs based on bioinformatics and key target reverse network pharmacology and experimental verification, Infect Agent Cancer, 18, 41, 10.1186/s13027-023-00520-z · DOI
- Sahebkar, 2014, Are curcuminoids effective C-reactive protein-lowering agents in clinical practice? Evidence from a meta-analysis, Phytother Res, 28, 10.1002/ptr.5045 · DOI
- Kotha, 2019, Curcumin: biological, pharmaceutical, nutraceutical, and analytical aspects, Molecules, 24, 10.3390/molecules24162930 · DOI
- Shi, 2017, The role of carbonyl reductase 1 in drug discovery and development, Expert Opin Drug Metab Toxicol, 13, 10.1080/17425255.2017.1356820 · DOI
- Fujiki, 1999, Mechanistic findings of green tea as cancer preventive for humans, Proc Soc Exp Biol Med, 220, 10.1046/j.1525-1373.1999.d01-38.x · DOI
- Zhang, 2021, Potential protective mechanisms of green tea polyphenol EGCG against COVID-19, Trends Food Sci Technol, 114, 11, 10.1016/j.tifs.2021.05.023 · DOI
- Shi, 2024, Bisphenol a downregulates GLUT4 expression by activating aryl hydrocarbon receptor to exacerbate polycystic ovary syndrome, Cell Commun Signal, 22, 28, 10.1186/s12964-023-01410-y · DOI
Metadata
- Authors
- Shao, F., Xu, S., Zhao, H., Zhang, F., Wang, X., & Wang, H.
- Affiliations
- Nanjing Medical University (CN)
- Shanghai University of Traditional Chinese Medicine (CN)
- State Key Laboratory of Reproductive Medicine (CN)
- Corresponding author
- Wang, Hui
- Venue
- Frontiers in Endocrinology
- Publisher
- Frontiers Media SA
- Published
- 2024-09-24
- Volume
- 15
- Pages
- 1420004-1420004
- ISSN
- 1664-2392 (ISSN-L)
- PMC
- PMC11458446
- OpenAlex
- W4402786028
- Cited by
- 8
- References
- 52
- Citations by year
- 2026: 5 · 2025: 3
- FWCI
- 3.15
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Frontiers in Endocrinology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- National Natural Science Foundation of China (82374225)
- Topics
- Health Sciences › Medicine › Reproductive Medicine › Ovarian function and disorders
- Health Sciences › Medicine › Reproductive Medicine › Reproductive Biology and Fertility
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic and Kidney Cyst Diseases
- Keywords
- polycystic ovary syndrome, nutrient supplementation, omega-3 fatty acids, betaine, berberine, curcumin, epigallocatechin gallate, metformin, dehydroepiandrosterone, vitamin D, calcium, survivin, CBR1, AHR, drug target genes, causal risk factors
- MeSH terms
- Nutrients, Female, Fertility, Humans, Polycystic Ovary Syndrome, Risk Factors, Fatty Acids, Omega-3, Dietary Supplements, Mendelian Randomization Analysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review